cannabis indica

Depressão

termo de indexação original: Depression

O acervo do Cannabis Indica reúne 486 estudos científicos que tocam a condição Depressão, publicados entre 1843 e 2024. Pela leitura automatizada, 298 (61%) foram classificados como favoráveis, 82 (17%) como inconclusivos e 106 (22%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (255 estudos), seguido de estudo em animais (80). Os compostos mais presentes são Anandamida (AEA), Endocanabinoide (não especificado) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Ansiedade, Dependência — Cannabis e Dor.

Estudos indexados
486
Período coberto
1843–2024
Favoráveis
298 · 61%
Inconclusivos
82 · 17%
Desfavoráveis
106 · 22%
Termo original
Depression

O acervo em números

Tipo de estudo

Metanálise255
Estudo em Animais80
Ensaio Clínico73
Ensaio Clínico Duplo-Cego43
Metanálise Clínica25
Estudo Laboratorial10

Direção do resultado

Favorável298
Inconclusivo82
Desfavorável106

Por década

1840s1
1890s1
1910s1
1990s1
2000s21
2010s156
2020s305

486 estudos

Filtrar e buscar no acervo →

Esta página mostra 334 dos 486 estudos indexados sobre o tema, dos mais recentes aos mais antigos. Abra o acervo com este filtro para percorrer todos, ou baixe a lista completa em JSON e CSV.

  1. 2024

    Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

    DesfavorávelMetanáliseAnsiedadeDisfunção CognitivaPsicose+4
  2. 2024

    Clinical, sociodemographic and environmental predicting factors for relapse in bipolar disorder: A systematic review

    DesfavorávelMetanáliseTranstorno Bipolar
  3. 2024

    Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisAnsiedade+3
  4. 2024

    Endocannabinoid levels in female-sexed individuals with diagnosed depression: a systematic review

    InconclusivoMetanáliseAnsiedadePsicoseEndocanabinoide (não especificado)
  5. 2024

    Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeInsônia e Distúrbios do SonoTEPT+2
  6. 2024

    Harmonization of clinical practice guidelines for primary prevention and screening: actionable recommendations and resources for primary care

    InconclusivoMetanáliseDependência QuímicaCâncerDependência — Cannabis+11
  7. 2024

    Moving to Improve Mental Health - The Role of Exercise in Cognitive Function: A Narrative Review

  8. 2024

    Perioperative Cannabis Use in Bariatric Patients: A Review of Outcomes and Proposed Clinical Pathway for Management

    DesfavorávelMetanáliseDorDependência QuímicaEfeitos Adversos da Cannabis+9
  9. 2024

    The Interplay of Sleep Quality, Mental Health, and Sociodemographic and Clinical Factors among Italian College Freshmen

    DesfavorávelEnsaio ClínicoDependência QuímicaAnsiedadePsicose+2
  10. 2024

    Understanding youth and young adult cannabis use in Canada post-legalization: a scoping review on a public health issue

    FavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDisfunção Cognitiva+2
  11. 2024

    Using Smartphone Technology to Track Real-Time Changes in Anxiety/Depression Symptomatology Among Florida Cannabis Users

    FavorávelMetanáliseAnsiedade
  12. 2024

    Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research

  13. 2023

    A case of panic attack developing after THC-O acetate inhalation using an e-cigarette device

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDisfunção Cognitiva+4
  14. 2023

    A systematic review of cannabidiol trials in neurodevelopmental disorders

    FavorávelMetanálise ClínicaDorInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+10
  15. 2023

    Alteration of faecal microbiota balance related to long-term deep meditation

  16. 2023

    An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry

    FavorávelMetanáliseDorAnsiedadeInsônia e Distúrbios do Sono+1
  17. 2023

    CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study

    FavorávelEnsaio Clínico Duplo-CegoTDA e TDAHTiques e Síndrome de TouretteQualidade de VidaTHC:CBD Farmacêutico
  18. 2023

    Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study

    FavorávelEnsaio Clínico Duplo-Cego
  19. 2023

    Cannabidiol repairs behavioral and brain disturbances in a model of fetal alcohol spectrum disorder

    FavorávelEstudo em AnimaisAnsiedadeDisfunção CognitivaEstresse OxidativoCanabicromeno (CBC)+4
  20. 2023

    Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use

  21. 2023

    Cannabidiol-enriched cannabis extraction product in Parkinson's disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDoença de ParkinsonInsuficiência RenalCBD Farmacêutico+1
  22. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  23. 2023

    Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats

    FavorávelEstudo em AnimaisAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  24. 2023

    Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

    InconclusivoMetanálise ClínicaDorDependência QuímicaCâncer+15
  25. 2023

    Cannabis use and sleep quality in daily life: An electronic daily diary study of adults starting cannabis for health concerns

    FavorávelEnsaio ClínicoDorInsônia e Distúrbios do Sono
  26. 2023

    Cannabis use for medical symptoms: Patterns over the first year of use

    FavorávelMetanáliseDorDependência QuímicaDependência — Cannabis+2
  27. 2023

    CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects

    FavorávelEstudo em Animais
  28. 2023

    Cocaine-Induced Raynaud's Phenomenon: A Case Report

  29. 2023

    Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial

  30. 2023

    Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership

    DesfavorávelEnsaio ClínicoDorDependência QuímicaEfeitos Adversos da Cannabis+3
  31. 2023

    Dramatic efficacy of cannabidiol on refractory chronic pain in an adolescent with sickle cell disease

  32. 2023

    Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies

    FavorávelMetanáliseInflamaçãoCOVID-19Palmitoiletanolamida (PEA)
  33. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  34. 2023

    Factors associated with suicide in people who use drugs: a scoping review

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+10
  35. 2023

    Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+2
  36. 2023

    Hippocampal CB1 receptor mediates antidepressant-like effect of synthetic cannabinoid-HU210 in acute despair reaction model in mice

    FavorávelEstudo em AnimaisEstresse OxidativoCanabinoides Sintéticos HU-x
  37. 2023

    How are young people’s mental health related to their sexual health and substance use? A systematic review of UK literature

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+4
  38. 2023

    Induction of Anxiety-Like Phenotypes by Knockdown of Cannabinoid Type-1 Receptors in the Amygdala of Marmosets

  39. 2023

    Involvement of cannabinoid receptors and neuroinflammation in early sepsis: Implications for posttraumatic stress disorder

  40. 2023

    Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studies

  41. 2023

    Mental health and substance use screening in HIV primary care before and during the early COVID-19 pandemic

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisAnsiedade+6
  42. 2023

    Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression

    InconclusivoMetanálise ClínicaCâncerAnsiedadePsicose+1
  43. 2023

    Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

    DesfavorávelEnsaio Clínico Duplo-CegoCâncerAnsiedadeCuidados Paliativos
  44. 2023

    Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection

    InconclusivoMetanálise ClínicaDorCâncerAnsiedadeTHC FarmacêuticoTHC:CBD Farmacêutico+9
  45. 2023

    Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

  46. 2023

    Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis

    DesfavorávelEnsaio ClínicoPsicoseEsquizofrenia
  47. 2023

    Retrospective chart review of substance abuse in patients with psychiatric emergencies in an emerging urban county

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDependência — CannabisAnsiedade+8
  48. 2023

    Reversible cerebral vasoconstriction syndrome associated with probable drug poisoning

  49. 2023

    Substance use and psychotic-like experiences in young people: a systematic review and meta-analysis

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+6
  50. 2023

    Synthetic Cannabinoids and ST-Elevated Myocardial Infarction: A Case Report and Literature Review

  51. 2023

    Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder

  52. 2023

    THC and CBD: Similarities and differences between siblings

    FavorávelMetanáliseEfeitos Adversos da CannabisAnsiedade
  53. 2023

    The effect of recreational cannabis legalization and commercialization on substance use, mental health, and injury: a systematic review

    DesfavorávelMetanálise ClínicaDependência QuímicaEfeitos Adversos da CannabisAnsiedade+1
  54. 2023

    The Effectiveness and Adverse Events of Cannabidiol and Tetrahydrocannabinol Used in the Treatment of Anxiety Disorders in a PTSD Subpopulation: An Interim Analysis of an Observational Study

    FavorávelMetanáliseAnsiedadeNáusea e VômitoTEPT+1
  55. 2023

    The effectiveness of oxytocin for treating substance use disorders:A systematic review of randomized placebo-controlled trials

    InconclusivoMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedade+5
  56. 2023

    The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials

  57. 2023

    The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders

    FavorávelEstudo em AnimaisResveratrol
  58. 2023

    The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse

    FavorávelEstudo em AnimaisDorInflamaçãoAnsiedadeEndocanabinoide (não especificado)+12
  59. 2022

    A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Palmitoiletanolamida (PEA)+5
  60. 2022

    A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System

  61. 2022

    Acute pancreatitis as a rare adverse event among cannabis users: A systematic review

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da CannabisAnandamida (AEA)+16
  62. 2022

    Adaptive Treatment for Youth With Substance Use and Depression: Early Depression Response and Short-term Outcomes

  63. 2022

    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaPsicoseEsquizofreniaAnandamida (AEA)Palmitoiletanolamida (PEA)+3
  64. 2022

    Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy

    InconclusivoEstudo LaboratorialAnsiedadeInsônia e Distúrbios do SonoGestação+1
  65. 2022

    An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample

    FavorávelMetanáliseAnsiedadeInsônia e Distúrbios do Sono
  66. 2022

    Association Between Prenatal Cannabis Use and Psychotropic Medication Use in Pregnant Patients With Depression and Anxiety

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+2
  67. 2022

    Association of cannabis potency with mental ill health and addiction: a systematic review

    DesfavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedadeTetraidrocanabinol (THC)+1
  68. 2022

    Associations between Cannabis Use, Cannabis Use Disorder and Mood Disorders: Longitudinal, Genetic, and Neurocognitive Evidence

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisTranstorno Bipolar+1
  69. 2022

    Attitudes and Beliefs of Cancer Patients Demanding Medical Cannabis Use in the North of Thailand

    FavorávelMetanáliseDorCâncerAnsiedade+5
  70. 2022

    Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems

  71. 2022

    Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems

  72. 2022

    Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder

    DesfavorávelMetanálise ClínicaDependência QuímicaEfeitos Adversos da CannabisDependência — Cannabis+3
  73. 2022

    Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists

    FavorávelMetanáliseAnsiedade
  74. 2022

    Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

  75. 2022

    Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses

    FavorávelEstudo em AnimaisDependência QuímicaAnsiedadePsicoseÁcido Canabidiólico (CBD-a)+4
  76. 2022

    Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

  77. 2022

    Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study

  78. 2022

    Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial

    InconclusivoEnsaio Clínico Duplo-CegoDorAnsiedadeArtriteCanabinoide Sintético (não especificado)
  79. 2022

    Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice

  80. 2022

    Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

    FavorávelMetanáliseInflamaçãoAnsiedadeDisfunção Cognitiva+4
  81. 2022

    Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department

  82. 2022

    Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

  83. 2022

    Cannabinoids-Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series

  84. 2022

    Cannabis and binge alcohol use among older individuals with major depressive episode

  85. 2022

    Cannabis and the Violent Crime Surge

    DesfavorávelMetanáliseEfeitos Adversos da CannabisPsicoseEsquizofrenia+4
  86. 2022

    Cannabis use among U.S. military veterans with subthreshold or threshold posttraumatic stress disorder: Psychiatric comorbidities, functioning, and strategies for coping with posttraumatic stress symptoms

    DesfavorávelMetanáliseDorDependência — CannabisAnsiedade+3
  87. 2022

    Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints

    FavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade
  88. 2022

    Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists

    FavorávelMetanáliseAnsiedadeInsônia e Distúrbios do SonoTEPTTHC Farmacêutico+1
  89. 2022

    Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry

  90. 2022

    Controlled Trial Examining the Strength-Based Grit Wellbeing and Self-Regulation Program for Young People in Residential Settings for Substance Use

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisAnsiedade+3
  91. 2022

    Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder

  92. 2022

    Cost-Effectiveness of Motivational Interviewing to Reduce Alcohol and Cannabis Use Among Patients With Depression

  93. 2022

    Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

  94. 2022

    Does cannabis use predict aggressive or violent behavior in psychiatric populations? A systematic review

    InconclusivoMetanáliseAnsiedadeDisfunção CognitivaPsicose+4
  95. 2022

    Dose-dependent alteration of neurobehavioral activities by geraniol a component of essential oil: A study in rats

    FavorávelEstudo em AnimaisAnsiedadeEstresse Oxidativo
  96. 2022

    E-Cigarette and Cannabis Use Patterns, Depression, and Suicide Behaviors Among US Youth: Analysis of 2019 Youth Risk Behavior Survey Data

  97. 2022

    Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial

    InconclusivoEnsaio ClínicoDorDependência — CannabisAnsiedade+4
  98. 2022

    Effects of 28 days of cannabis abstinence on cognition in major depressive disorder: A pilot study

  99. 2022

    Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoAnsiedadeEstresse Oxidativo
  100. 2022

    Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer

    FavorávelEnsaio Clínico Duplo-CegoTEPTHidrolase de Amidas de Ácidos Graxos (FAAH)
  101. 2022

    Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review

    InconclusivoMetanáliseAnsiedade
  102. 2022

    Frequent Cannabis Use Moderates the Relationship Between Sexual Dysfunction and Depression Among Female German Adults

  103. 2022

    Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies

    InconclusivoMetanáliseAnsiedadePsicoseEsquizofrenia
  104. 2022

    Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedade+5
  105. 2022

    Harm Reduction Strategies among University Students Who Use Alcohol and Cannabis, and Related Psychological Variables: A Systematic Review

  106. 2022

    Higher Risk, Higher Reward? Self‐Reported Effects of Real‐World Cannabis Use in Parkinson's Disease

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+2
  107. 2022

    Hypertensive Crisis-Related Hospitalizations and Subsequent Major Adverse Cardiac Events in Young Adults with Cannabis Use Disorder: A Nationwide Analysis

  108. 2022

    Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis

  109. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  110. 2022

    Impact of cannabinoids on pregnancy, reproductive health and offspring outcomes

    DesfavorávelMetanáliseDorDependência QuímicaCâncerTHC:CBD Farmacêutico+14
  111. 2022

    Improved Therapeutic Efficacy of CBD with Good Tolerance in the Treatment of Breast Cancer through Nanoencapsulation and in Combination with 20(S)-Protopanaxadiol (PPD)

    FavorávelEstudo LaboratorialDorCâncerAnsiedade+3
  112. 2022

    In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer center

    FavorávelMetanáliseDorCâncerAnsiedade+14
  113. 2022

    In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters

  114. 2022

    Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaEstresse Oxidativo+4
  115. 2022

    Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder

    FavorávelMetanáliseDorCâncerInflamaçãoTetraidrocanabinol (THC)+10
  116. 2022

    Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies

    DesfavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)THC Farmacêutico+14
  117. 2022

    Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: A systematic review and meta-analysis of effectiveness and safety

  118. 2022

    Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale

    DesfavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedade+3
  119. 2022

    Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review

  120. 2022

    Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  121. 2022

    Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study

    FavorávelMetanáliseAnsiedade
  122. 2022

    Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease

  123. 2022

    Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review

  124. 2022

    Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience

    InconclusivoEnsaio ClínicoAyahuasca
  125. 2022

    Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

    InconclusivoMetanáliseAnsiedadeAnandamida (AEA)Endocanabinoide (não especificado)+8
  126. 2022

    Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant

    FavorávelMetanáliseEndocanabinoide (não especificado)Ayahuasca
  127. 2022

    Neuropsychological functioning and suicidal behaviours in patients with first-episode psychosis: A systematic review

  128. 2022

    Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry

    FavorávelMetanáliseAyahuasca
  129. 2022

    Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health

  130. 2022

    Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoEpilepsiaTetraidrocanabinol (THC)Monoacilglicerol Lipase (MAGL)+2
  131. 2022

    Predictors of pain reduction among fibromyalgia patients using medical cannabis: a long-term prospective cohort study

    FavorávelEnsaio ClínicoDorAnsiedadeDor — Crônica+2
  132. 2022

    Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition

    DesfavorávelMetanáliseDorDependência QuímicaCâncerTetraidrocanabinol (THC)+12
  133. 2022

    Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada

    FavorávelMetanáliseDorDor — CrônicaPsicose+5
  134. 2022

    Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadePsicose+2
  135. 2022

    Recreational cannabis legalizations associated with reductions in prescription drug utilization among Medicaid enrollees

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+3
  136. 2022

    Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

    DesfavorávelEnsaio Clínico Duplo-CegoAnsiedadeDoenças Cardiovasculares (DCV)ObesidadeCanabinoides Sintéticos SR-x+1
  137. 2022

    Shifting the Paradigm on Cannabis Safety

    DesfavorávelMetanáliseCâncerInflamaçãoEfeitos Adversos da CannabisCBD Farmacêutico+16
  138. 2022

    Synaptic changes induced by cannabinoid drugs and cannabis use disorder

  139. 2022

    Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report

  140. 2022

    The antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a preclinical systematic review and meta-analysis

    FavorávelMetanáliseAnsiedade
  141. 2022

    The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder

  142. 2022

    The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls

  143. 2022

    The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes

    FavorávelMetanálise ClínicaDorCâncerAnsiedade+5
  144. 2022

    The effect of β-caryophyllene on food addiction and its related behaviors: A randomized, double-blind, placebo-controlled trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeObesidadeTranstornos de ComportamentoEndocanabinoide (não especificado)
  145. 2022

    The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study

    FavorávelEnsaio ClínicoDorAnsiedadeDor — Crônica+3
  146. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  147. 2022

    The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety

    InconclusivoMetanáliseAnsiedadeAnandamida (AEA)Endocanabinoide (não especificado)+3
  148. 2022

    The Medicinal Natural Products of Cannabis sativa Linn.: A Review

  149. 2022

    The modulatory effects of alkaloid extracts of Cannabis sativa, Datura stramonium, Nicotiana tabacum and male Carica papaya on neurotransmitter, neurotrophic and neuroinflammatory systems linked to anxiety and depression

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeEstresse Oxidativo
  150. 2022

    The relationship between anxious-depressive symptoms and harmful cannabis use: Multiple mediation models via rumination, negative urgency, protective behavioral strategies and refusal self-efficacy

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedade
  151. 2022

    Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor

    FavorávelEstudo em AnimaisDorCâncerInflamação+16
  152. 2022

    TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids

  153. 2022

    UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes

    FavorávelMetanáliseDorAnsiedadeDor — Oncológica+1
  154. 2022

    Unexpected short- and long-term effects of chronic adolescent HU-210 exposure on emotional behavior

  155. 2022

    United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020

    InconclusivoMetanáliseCâncerAnsiedadeTEPTAyahuasca+2
  156. 2022

    Variations of cannabis-related adverse mental health and addiction outcomes across adolescence and adulthood: A scoping review

  157. 2021

    [Efficacy of psychedelics in psychiatry, a systematic review of the literature]

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedadeAyahuasca+7
  158. 2021

    A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats

    InconclusivoEnsaio ClínicoAnsiedadeAyahuasca
  159. 2021

    A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisAnsiedade+2
  160. 2021

    A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis

    FavorávelMetanáliseInflamaçãoAnsiedadeDisfunção Cognitiva+5
  161. 2021

    A study of abnormal cannabidiols system-mediated cardiovascular protection in disrupted gut/brain axis associated depression

  162. 2021

    A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness

    DesfavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisPsicose+2
  163. 2021

    A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders

  164. 2021

    Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol

    FavorávelMetanáliseDorDependência QuímicaInflamação+7
  165. 2021

    Anticonvulsant, Anxiolytic and Antidepressant Properties of the β-caryophyllene in Swiss Mice: Involvement of Benzodiazepine-GABAAergic, Serotonergic and Nitrergic Systems

    FavorávelEstudo em AnimaisAnsiedadeEpilepsia
  166. 2021

    Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial

    FavorávelMetanáliseAnsiedade
  167. 2021

    Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure

    FavorávelEstudo em AnimaisDependência QuímicaDependência — Opioides
  168. 2021

    Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents

    InconclusivoEnsaio ClínicoAnsiedade
  169. 2021

    Associations among marijuana use, health-related quality of life, exercise, depression and sleep in cancer survivors

    DesfavorávelMetanálise
  170. 2021

    Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDisfunção CognitivaAyahuasca
  171. 2021

    Cannabidiol (CBD) as a novel treatment in the early phases of psychosis

    FavorávelMetanáliseAnsiedadePsicoseEsquizofrenia
  172. 2021

    Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment

    InconclusivoMetanáliseDependência QuímicaAnsiedadeEpilepsia+10
  173. 2021

    Cannabidiol and Neurodevelopmental Disorders in Children

  174. 2021

    Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways

    FavorávelEstudo em AnimaisInflamação
  175. 2021

    Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research

    FavorávelMetanáliseAnsiedade
  176. 2021

    Cannabidiol for Mood Disorders: A Call for More Research

    DesfavorávelMetanáliseDorDor — CrônicaDisfunção Cognitiva+3
  177. 2021

    Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study

    InconclusivoEnsaio Clínico Duplo-CegoDependência QuímicaInflamaçãoDependência — CannabisAnandamida (AEA)+8
  178. 2021

    Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: The role of medial prefrontal cortex 5-HT 1A and CB 1 receptors

  179. 2021

    Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

  180. 2021

    Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain

    FavorávelEstudo em AnimaisInflamaçãoDoenças Neurodegenerativas
  181. 2021

    Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic

    FavorávelMetanáliseDorAnsiedade
  182. 2021

    Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain

    FavorávelMetanáliseDorEfeitos Adversos da CannabisAnsiedade+8
  183. 2021

    Cannabinoids and bladder symptoms in multiple sclerosis

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+4
  184. 2021

    Cannabis and Depression

    InconclusivoMetanálise
  185. 2021

    Cannabis Consumption Onset and Addiction: Data from the Second Brazilian Drugs and Alcohol Survey (BNADS)

  186. 2021

    Cannabis Use and Mental Illness: Understanding Circuit Dysfunction Through Preclinical Models

  187. 2021

    Cannabis Use in People With Obsessive-Compulsive Symptomatology: Results From a Mexican Epidemiological Sample

  188. 2021

    Cannabis-induced oceanic boundlessness

    FavorávelEnsaio ClínicoDorDependência — ÁlcoolDependência — Nicotina+2
  189. 2021

    Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications

    InconclusivoMetanáliseDependência — CannabisAnsiedadeDependência — Opioides+2
  190. 2021

    Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus

    FavorávelEstudo em Animais
  191. 2021

    Circulating endocannabinoids and prospective risk for depression in trauma-injury survivors

    InconclusivoMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  192. 2021

    Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People

    DesfavorávelEstudo LaboratorialAnsiedade
  193. 2021

    Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects

    FavorávelEstudo em Animais
  194. 2021

    Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

  195. 2021

    Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC

    FavorávelMetanáliseDorAnsiedadeDor — CrônicaDelta-8-THC+1
  196. 2021

    Correlates of High HIV Viral Load and Antiretroviral Therapy Adherence Among Viremic Youth in the United States Enrolled in an Adherence Improvement Intervention

    DesfavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisHIV/AIDS
  197. 2021

    Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?

    FavorávelMetanáliseAnsiedadeInsônia e Distúrbios do SonoTEPT+1
  198. 2021

    Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder

  199. 2021

    Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+1
  200. 2021

    Down and High: Reflections Regarding Depression and Cannabis

    DesfavorávelMetanáliseDependência QuímicaDependência — Cannabis
  201. 2021

    Early-life stress induces emotional and molecular alterations in female mice that are partially reversed by cannabidiol

  202. 2021

    Effects of a Novel GPR55 Antagonist on the Arachidonic Acid Cascade in LPS-Activated Primary Microglial Cells

  203. 2021

    Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic

    FavorávelEnsaio ClínicoAnsiedade
  204. 2021

    Emotion regulation in emerging adults with major depressive disorder and frequent cannabis use

    InconclusivoEnsaio ClínicoDependência — Cannabis
  205. 2021

    Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study

  206. 2021

    Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort

  207. 2021

    Endocannabinoid-serotonin systems interaction in health and disease

  208. 2021

    Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review

    InconclusivoMetanálise ClínicaAnsiedadeTEPTTranstorno Bipolar
  209. 2021

    Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisAnsiedade+2
  210. 2021

    Further evidence of anxiety- and depression-like behavior for total genetic ablation of cannabinoid receptor type 1

    FavorávelEstudo em AnimaisAnsiedade
  211. 2021

    Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research

    FavorávelMetanáliseDorDependência QuímicaCâncer+16
  212. 2021

    Impact of a computerized intervention for high distress intolerance on cannabis use outcomes: A randomized controlled trial

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisAnsiedade
  213. 2021

    Impact of Acute and Chronic Cannabis Use on Stress Response Regulation: Challenging the Belief That Cannabis Is an Effective Method for Coping

  214. 2021

    Impact of COVID-19 on Mental Health in Adolescents: A Systematic Review

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+1
  215. 2021

    Impact of saffron (Crocus Sativus Linn) supplementation and resistance training on markers implicated in depression and happiness levels in untrained young males

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeAnandamida (AEA)Hidrolase de Amidas de Ácidos Graxos (FAAH)
  216. 2021

    Inhibition of Fatty Acid Amide Hydrolase (FAAH) During Adolescence and Exposure to Early Life Stress may Exacerbate Depression-like Behaviors in Male and Female Rats

    FavorávelEstudo em AnimaisHidrolase de Amidas de Ácidos Graxos (FAAH)
  217. 2021

    Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression

    FavorávelMetanálise2-Araquidonoilglicerol (2-AG)
  218. 2021

    Limonene through Attenuation of Neuroinflammation and Nitrite Level Exerts Antidepressant-Like Effect on Mouse Model of Maternal Separation Stress

    FavorávelEstudo em AnimaisInflamação
  219. 2021

    Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review

    FavorávelMetanálise
  220. 2021

    Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder

  221. 2021

    Marijuana, but not alcohol, use frequency associated with greater loneliness, psychological distress, and less flourishing among young adults

    DesfavorávelMetanáliseAnsiedade
  222. 2021

    Medical Cannabis as a Substitute for Prescription Agents: A Systematic Review and Meta-analysis

    FavorávelMetanáliseDorAnsiedadeDor — Crônica
  223. 2021

    Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?

    InconclusivoMetanáliseDorCâncerAnsiedade+5
  224. 2021

    Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects

    FavorávelMetanáliseDorCâncerAnsiedade+5
  225. 2021

    Mixed methods study of the potential therapeutic benefits from medical cannabis for patients in Florida

    FavorávelMetanáliseDorDor — CrônicaEpilepsia+6
  226. 2021

    Moderator effects in a randomized controlled trial of the Common Elements Treatment Approach (CETA) for intimate partner violence and hazardous alcohol use in Zambia

  227. 2021

    Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent?

    FavorávelMetanáliseDorCâncerInflamaçãoEndocanabinoide (não especificado)+9
  228. 2021

    Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome

  229. 2021

    P.0835 Synergistic effects of lysergic acid diethylamide (LSD) and cannabidiol (CBD)

    FavorávelEstudo em Animais
  230. 2021

    Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III

    DesfavorávelMetanáliseDorDependência — CannabisAnsiedade+2
  231. 2021

    Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer

    FavorávelMetanáliseDorCâncerDor — Crônica+7
  232. 2021

    Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study

  233. 2021

    Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders

    FavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeEpilepsia+8
  234. 2021

    Prevalence, sociodemographic variables, mental health condition, and type of drug use associated with suicide behaviors among people with substance use disorders: a systematic review and meta-analysis

  235. 2021

    Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases

  236. 2021

    Prospects for the Use of Cannabinoids in Psychiatric Disorders

    InconclusivoMetanáliseAnsiedadeInsônia e Distúrbios do SonoDemência
  237. 2021

    Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients

  238. 2021

    Psychosis induced by abuse of ayahuasca: a case report

    DesfavorávelMetanáliseAnsiedadePsicoseEsquizofreniaAyahuasca+1
  239. 2021

    Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisAnsiedade+1
  240. 2021

    Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

    FavorávelEnsaio ClínicoTentativa de SuicídioAyahuasca
  241. 2021

    Recent updates on bioactive properties of linalool

    FavorávelMetanáliseCâncerAnsiedadeDoenças Neurodegenerativas+1
  242. 2021

    Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

    FavorávelMetanáliseDorAnsiedadeDor — CrônicaCanabigerol (CBG)+1
  243. 2021

    Targeting 2-arachidonoylglycerol signalling in the neurobiology and treatment of depression

  244. 2021

    Targeting the endocannabinoid system with microbial interventions to improve gut integrity

  245. 2021

    Telephone veteran peer coaching for mental health treatment engagement among rural veterans: The importance of secondary outcomes and qualitative data in a randomized controlled trial

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisTEPT+1
  246. 2021

    The cannabinoid system and microglia in health and disease

  247. 2021

    The Current and Potential Application of Medicinal Cannabis Products in Dentistry

  248. 2021

    The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  249. 2021

    The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  250. 2021

    The relation between cannabis use, dependence severity and white matter microstructure: A diffusion tensor imaging study

  251. 2021

    Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial

    FavorávelEnsaio Clínico Duplo-CegoDependência QuímicaDependência — CannabisAnsiedade+1
  252. 2021

    Young Aboriginal people in Australia who have never used marijuana in the ‘Next Generation Youth Well-being study’: A strengths-based approach

    DesfavorávelEnsaio ClínicoEfeitos Adversos da CannabisAnsiedade
  253. 2020

    A Little Dab Will Do: A Case of Cannabis-Induced Psychosis

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDependência — CannabisAnsiedade+4
  254. 2020

    A systematic review of cigarette smoking trajectories in adolescents

  255. 2020

    Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study

  256. 2020

    Antidepressant-Like Effect of Terpineol in an Inflammatory Model of Depression: Involvement of the Cannabinoid System and D2 Dopamine Receptor

    FavorávelEstudo em AnimaisCanabinoides Sintéticos AM-x
  257. 2020

    Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression

    FavorávelEstudo em AnimaisDorInflamação
  258. 2020

    Associating Emergency Medical Services personnel's workload, trauma exposure, and health with the cortisol, endocannabinoid, and N-acylethanolamine concentrations in their hair

  259. 2020

    Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

  260. 2020

    Cannabidiol as a Treatment for Mood Disorders: A Systematic Review

    InconclusivoMetanáliseAnsiedadeTranstorno Bipolar
  261. 2020

    Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression

  262. 2020

    Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

    FavorávelMetanáliseAnsiedadePsicose
  263. 2020

    Cannabinoid Hyperemesis Syndrome: A Case Report and Discussion Regarding Patients with Concurrent Disorders

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisPsicose+9
  264. 2020

    Cannabis use during pregnancy in the United States: The role of depression

    InconclusivoMetanáliseGestação
  265. 2020

    Cannabis use, depression and self-harm: phenotypic and genetic relationships

    InconclusivoMetanáliseTentativa de Suicídio
  266. 2020

    Cannabis use, depression and suicidal ideation in adolescence: direction of associations in a population based cohort

    InconclusivoMetanáliseTentativa de Suicídio
  267. 2020

    Capsaicin Is a Negative Allosteric Modulator of the 5-HT3 Receptor

    FavorávelEstudo LaboratorialDorAnsiedadeEsquizofreniaCapsaicina (CAPS)+2
  268. 2020

    CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim

    FavorávelEstudo em AnimaisDisfunção CognitivaTranstornos de ComportamentoTEPT
  269. 2020

    Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

    FavorávelEnsaio ClínicoInflamaçãoAyahuasca
  270. 2020

    Combined prevention for substance use, depression, and anxiety in adolescence: a cluster-randomised controlled trial of a digital online intervention

  271. 2020

    Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review

    FavorávelMetanáliseCúrcuma
  272. 2020

    Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?

    DesfavorávelMetanáliseCâncerDoença de AlzheimerDiabetes+1
  273. 2020

    Depressive symptoms moderate cannabis use for young adults in a Text-Delivered randomized clinical trial for cannabis use disorder

  274. 2020

    Diacylglycerol lipase alpha in astrocytes is involved in maternal care and affective behaviors

    InconclusivoEstudo em AnimaisGestação2-Araquidonoilglicerol (2-AG)Monoacilglicerol Lipase (MAGL)
  275. 2020

    Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system

    FavorávelEstudo em AnimaisEndocanabinoide (não especificado)Microbioma
  276. 2020

    Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression

    FavorávelEstudo em Animais
  277. 2020

    Increased Anandamide and Decreased Pain and Depression after Exercise in Fibromyalgia

  278. 2020

    Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals

    FavorávelMetanáliseCâncerAnsiedadeDoenças Cardiovasculares (DCV)+6
  279. 2020

    Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoDorInsônia e Distúrbios do SonoFibromialgiaCanabigerol (CBG)Canabinol (CBN)+3
  280. 2020

    Inhalation Administration of the Bicyclic Ethers 1,8- and 1,4-cineole Prevent Anxiety and Depressive-Like Behaviors in Mice

    FavorávelEstudo em AnimaisAnsiedade
  281. 2020

    Inner Engineering Practices and Advanced 4-day Isha Yoga Retreat Are Associated with Cannabimimetic Effects with Increased Endocannabinoids and Short-Term and Sustained Improvement in Mental Health: A Prospective Observational Study of Meditators

  282. 2020

    Link between personality and response to THC exposure

    InconclusivoEstudo em AnimaisEfeitos Adversos da CannabisAnsiedade
  283. 2020

    Mapping cannabis potency in medical and recreational programs in the United States

    DesfavorávelMetanáliseDorAnsiedadeDor — CrônicaTetraidrocanabinol (THC)+4
  284. 2020

    Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

    FavorávelMetanáliseAnsiedadePsicoseInsônia e Distúrbios do Sono+3
  285. 2020

    Moderating role of cannabis use between insight and depression in early psychosis

    InconclusivoMetanálisePsicoseEsquizofrenia
  286. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  287. 2020

    Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis

    FavorávelEstudo em AnimaisObesidadeSíndrome MetabólicaPalmitoiletanolamida (PEA)
  288. 2020

    Parsing impulsivity in individuals with anxiety and depression who use Cannabis

    DesfavorávelEnsaio ClínicoEfeitos Adversos da CannabisAnsiedade
  289. 2020

    Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology

  290. 2020

    Prevalence of Common Mental Disorders in South Asia: A Systematic Review and Meta-Regression Analysis

  291. 2020

    Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis

    DesfavorávelMetanálise ClínicaAnsiedadeDisfunção CognitivaPsicose
  292. 2020

    Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior

    FavorávelEstudo em AnimaisAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  293. 2020

    Safety and Efficacy of Cannabis in Autism Spectrum Disorder

    FavorávelMetanáliseAnsiedadeDisfunção CognitivaAutismo+1
  294. 2020

    Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats

  295. 2020

    Temporal Changes in the Cross-Sectional Associations between Cannabis Use, Suicidal Ideation, and Depression in a Nationally Representative Sample of Canadian Adults in 2012 Compared to 2002

    DesfavorávelMetanáliseTentativa de Suicídio
  296. 2020

    Temporal dynamics of the relationship between change in depressive symptoms and cannabis use in adolescents receiving psychosocial treatment for cannabis use disorder

  297. 2020

    Terpenes/Terpenoids in Cannabis: Are They Important?

    FavorávelMetanáliseDorCâncerInflamação+10
  298. 2020

    The Cannabis Terpenes

    FavorávelMetanáliseDorCâncerInflamação+10
  299. 2020

    The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression

    FavorávelMetanálise
  300. 2020

    The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials

    InconclusivoMetanálise ClínicaAnsiedade
  301. 2019

    Cannabinoids in depressive disorders

    FavorávelMetanálise
  302. 2019

    Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users

    InconclusivoMetanáliseDependência — CannabisAnsiedade
  303. 2019

    Demographic, Cannabis Use, and Depressive Correlates of Cannabis Use Consequences in Regular Cannabis Users

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  304. 2019

    Effects of cannabidiol in males and females in two different rat models of depression

    FavorávelMetanálise
  305. 2019

    Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms

    FavorávelMetanálise
  306. 2019

    Interrelationships among depression, anxiety, flourishing, and cannabis use in youth

    InconclusivoMetanáliseAnsiedade
  307. 2019

    Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system

    FavorávelEstudo em Animais
  308. 2019

    Marijuana use and major depressive disorder are additively associated with reduced verbal learning and altered cortical thickness

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  309. 2019

    Medical Marijuana Dependence Among Chronic Pain Patients Suffering From Depression and Anxiety

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDependência — Cannabis+2
  310. 2019

    Motives Matter: Cannabis use motives moderate the associations between stress and negative affect

    InconclusivoMetanáliseAnsiedade
  311. 2019

    Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis

    InconclusivoMetanáliseDorAnsiedadeDor — Crônica
  312. 2019

    The "entourage effect": Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders

    FavorávelMetanálise
  313. 2019

    The effectiveness of chair work intervention on anxiety and depression in divorced women using Cannabis

    FavorávelEnsaio ClínicoEfeitos Adversos da CannabisAnsiedade
  314. 2018

    Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels

    FavorávelEstudo em Animais
  315. 2018

    Integrating endocannabinoid signaling in the regulation of anxiety and depression

    InconclusivoMetanáliseAnsiedadeEndocanabinoide (não especificado)
  316. 2018

    Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene.

    FavorávelEstudo em Animais
  317. 2018

    Negative urgency partially accounts for the relationship between major depressive disorder and marijuana problems

    InconclusivoMetanáliseDependência — Cannabis
  318. 2018

    Orbitofrontal connectivity is associated with depression and anxiety in marijuana-using adolescents

    InconclusivoEnsaio ClínicoEfeitos Adversos da CannabisAnsiedade
  319. 2018

    The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine

    InconclusivoMetanáliseDependência — Cannabis
  320. 2017

    Borneol enhances the antidepressant effects of asiaticoside by promoting its distribution into the brain

    FavorávelEstudo em Animais
  321. 2016

    Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents

  322. 2016

    Prohedonic Effect of Cannabidiol in a Rat Model of Depression.

    FavorávelEstudo em Animais
  323. 2015

    Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats

    InconclusivoEstudo em AnimaisAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  324. 2015

    Efficacy of Silexan in Mixed anxiety-depression--A Randomized, Placebo-Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedade
  325. 2013

    A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders

    DesfavorávelEnsaio Clínico Duplo-CegoDependência QuímicaDependência — Cannabis
  326. 2013

    The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeTetraidrocanabinol (THC)
  327. 2012

    [Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs]

  328. 2012

    Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression

    FavorávelEnsaio ClínicoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  329. 2011

    Alterations in Corticolimbic Dendritic Morphology and Emotional Behavior in Cannabinoid CB1 Receptor–Deficient Mice Parallel the Effects of Chronic Stress.

    FavorávelEstudo em AnimaisAnsiedade
  330. 2011

    Endocannabinoids and stress

    FavorávelMetanáliseAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  331. 2010

    Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults

    DesfavorávelEnsaio Clínico Duplo-CegoDependência QuímicaDependência — Cannabis
  332. 2010

    Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers

    DesfavorávelEnsaio Clínico Duplo-Cego
  333. 2008

    Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders.

    FavorávelMetanáliseEndocanabinoide (não especificado)
  334. 2007

    Does occasional cannabis use impact anxiety and depression treatment outcomes?: Results from a randomized effectiveness trial

    DesfavorávelEnsaio ClínicoAnsiedadeTetraidrocanabinol (THC)

Continue por aqui

Perguntas frequentes

Quantos estudos sobre depressão estão indexados no acervo?
São 486 estudos, publicados entre 1843 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 255 · Estudo em Animais: 80 · Ensaio Clínico: 73 · Ensaio Clínico Duplo-Cego: 43 · Metanálise Clínica: 25 · Estudo Laboratorial: 10. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 298 favoráveis, 82 inconclusivos e 106 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Depressão — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/depressao/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Depressão — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/depressao/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.